[MSB-12] Our Clinical Experience with Septal Myectomy in Hypertrophic Cardiomyopathy Patients
Hypertrophic cardiomyopathy is a genetic cardiac disorder with a heterogeneous spectrum of clinical manifestations. Septal reduction therapies are the primary treatment for patients. Septal myectomy has been shown to be effective, providing a reduction in outflow tract gradient and symptoms. Currently, myectomy is the recommended treatment for HCM, and it can be performed via conventional median sternotomy or minimally invasive approaches.
Authors
- Tayfun Özdem (ORCID: https://orcid.org/0000-0001-9605-7543)
- Emre Kubat (ORCID: https://orcid.org/0000-0002-9884-8565)
- Tuna Demirkıran (ORCID: https://orcid.org/0000-0001-5254-3339)
- Murat Kadan (ORCID: https://orcid.org/0000-0002-3385-7823)
- Kubilay Karabacak (ORCID: https://orcid.org/0000-0002-6290-1571)
- Furkan Burak Akyol (ORCID: https://orcid.org/0000-0002-6682-9386)
Institutions
- Gülhane Askerî Tıp Akademisi (TR)
Publication Details
- Journal
- Turkish Journal of Thoracic and Cardiovascular Surgery
- Published
- 2024-11-01
- DOI
- https://doi.org/10.5606/tgkdc.dergisi.2024.msb-12
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00